Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate (SURV-SEP)
Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEP
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Terminated
Another surveillance protocol was initiated by the OFSEP (OFSEP cohort) which allows to follow all the patients, whatever their treatment.
Other terminated trials from Fondation Ophtalmologique Adolphe de Rothschild
- Cervical Dystonia · Jul 2025
- Meningioma · Jun 2025
- Endolymphatic Hydrops · Apr 2025
- Hereditary Retinal Dystrophies · Mar 2025
- Brain Arteriovenous Malformations · Feb 2025
See all terminations from Fondation Ophtalmologique Adolphe de Rothschild
Other Multiple Sclerosis, Relapsing-Remitting trials with similar outcome
A PHASE4 clinical study on Multiple Sclerosis, Relapsing-Remitting, this trial is terminated or withdrawn. The trial is conducted by Fondation Ophtalmologique Adolphe de Rothschild and has accumulated 10 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 5 earlier versions
-
Feb 2019 — Nov 2020 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE4
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fondation Ophtalmologique Adolphe de Rothschild
For direct contact, visit the study record on ClinicalTrials.gov .